Hualan Biological Engineering Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St · 08/30 22:34

Hualan Biological Engineering (SZSE:002007) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥865.4m (up 23% from 2Q 2023).
  • Net income: CN¥178.4m (up 2.0% from 2Q 2023).
  • Profit margin: 21% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses.
  • EPS: CN¥0.098 (up from CN¥0.096 in 2Q 2023).
earnings-and-revenue-growth
SZSE:002007 Earnings and Revenue Growth August 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hualan Biological Engineering Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 29%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Valuation

It's possible that Hualan Biological Engineering could be undervalued with our 6-factor valuation analysis indicating a potential opportunity. Click here to find out what a fair price for the stock might be and where analysts see the share price heading over the next year.